BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38084880)

  • 1. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
    Symes E; Tjota M; Cody B; Kindler H; Mitchell O; Witmer H; Turaga K; Mueller J; Krausz T; Husain AN; Li H
    Histopathology; 2024 Feb; 84(3):492-506. PubMed ID: 38084880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report.
    Fels Elliott DR; Travieso JL; As-Sanie S; Hrycaj SM; Lieberman RW; Myers JL; Huang T
    Int J Gynecol Pathol; 2022 Sep; 41(5):535-540. PubMed ID: 34723845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
    J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant mesothelioma in situ: morphologic features and clinical outcome.
    Churg A; Galateau-Salle F; Roden AC; Attanoos R; von der Thusen JH; Tsao MS; Chang N; De Perrot M; Dacic S
    Mod Pathol; 2020 Feb; 33(2):297-302. PubMed ID: 31375770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant mesothelioma in situ: diagnostic and clinical considerations.
    Pulford E; Henderson DW; Klebe S
    Pathology; 2020 Oct; 52(6):635-642. PubMed ID: 32829890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
    Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
    Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well differentiated papillary mesothelial tumor: a new name and new problems.
    Churg A; Galateau-Salle F
    Mod Pathol; 2022 Oct; 35(10):1327-1333. PubMed ID: 35440764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
    Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
    Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.
    Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y
    Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
    Kittaneh M; Berkelhammer C
    J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
    Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
    Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.